Revitalist Executes on Mission to Build a National Network of Ketamine Clinics

Psychedelics have shown tremendous promise in treating depression, anxiety, post-traumatic stress disorder, and a range of other mental health conditions. In particular, assisted psychotherapy combines psychedelic substances with talk therapy to facilitate breakthroughs and help patients that don’t see relief through conventional treatments.

While psilocybin, MDMA, and other psychedelic medicines remain in clinical trials, the FDA already approved ketamine for anesthesia years ago and recently approved esketamine for treatment-resistant depression and suicidal ideations. As a result, ketamine clinics already offer mental health treatments to patients nationwide.

Revitalist Lifestyle & Wellness Ltd. (CSE: CALM) (OTC: RVLWF) is one of the few companies executing on a vision to build a nationwide network of ketamine clinics. The goal is to establish a clinical presence and build relationships early on with patients benefiting from ketamine treatments,  before expanding into other psychedelic substances as the FDA approves them for use.

Click here to learn more about investing in Revitalist

A Growing National Footprint

Revitalist recently acquired its ninth ketamine clinic, expanding its footprint across six states, including Florida, Kentucky, Tennessee, Michigan, North Carolina, and Washington DC. By the end of the year, the company hopes to open a total of 48 clinics before ultimately reaching over 150 clinics by 2025, cementing its leadership position in the industry.

The company provides several treatment options at these locations. For example, its intensive outpatient program (IOP) offers short-term treatment for worsening mental health conditions. The three-day-a-week, six-week program generates $6,000 in revenue per patient, with three-quarters of the cost reimbursed by health insurance.

Management projects that the company will reach 42,600 patients with 52,200 cumulative visits generating $15.8 million in revenue by the end of 2022. Of course, the company aims to grow these figures to nearly 600,000 patients, one million visits, and $223 million in annual revenue by 2025 as it reaches its target footprint of over 150 clinics. Revitalist recently announced a 128% increase in patient visits for the year ending 2021.

Disciplined Growth with Vision

Revitalist believes that each clinic will generate revenue of about $3 million with EBITDA of $1 million and 70% gross margins. In addition, since there are minimal upfront capital costs, these acquisitions are very quickly accretive. As a result, the company plans on breaking even over the next two years—not the 5+ years most medical companies take.

While many emerging psychedelic companies carry a lot of debt, Revitalist reported $3,701,190 in shareholders’ equity, as of September 30, 2021, with no non-lease-related long-term debt. The clean balance sheet means that shareholders don’t need to worry about a large debt load or other toxic debt that could be difficult to emerge from in the future.

Click here to learn more about investing in Revitalist

In addition to its disciplined growth, its management team is continuously looking to the future. For instance, the company recently acquired a 60% interest in Revitaland Meta Tech Inc. to create virtual clinics in the metaverse. These capabilities could dramatically expand its addressable market to those not located near one of its clinics.

Looking Ahead

Revitalist Lifestyle & Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) offers investors a unique opportunity to capitalize on the psychedelic revolution. Rather than incurring a lot of debt and then waiting for FDA approvals, investors can partake in a business that’s already generating revenue and approaching profitability in the space.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.